Experts discuss the phase III SIERRA trial, which recently demonstrated durable complete responses in patients with acute myeloid leukemia<br />
Case 1: Primary Induction Failure (PIF)
Case 2: Early Relapse with Remission <6 months
Disease State of AML
SIERRA Trial Design
Hematopoietic
Hillard M. Lazarus, MD, FACP - Case Western Reserve University
Rajneesh Nath, MD - Banner MD Anderson Cancer Center Clinic
Alexander E. Perl, MD, MS - Hospital of the University of Pennsylvania
Dramatic Changes in the RCC Landscape Underscore Importance of Molecular Profiling
June 8th 2023In an interview with Targeted Oncology, Alexander Helfand, MD discussed the current standard practice for testing patients with renal cell carcinoma and administering immunotherapy or targeted therapy.
Read More
Guidance on Treating GIST in the Second-Line and Beyond
May 30th 2023In an interview with Targeted Oncology, Alexander Helfand, MD, discussed the treatment of GIST in the second-line setting, as well as later lines, including the available options, guideline recommendations, and ongoing research.
Read More
2 Clarke Drive
Cranbury, NJ 08512